High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma A Multicenter, International Data-Sharing American Joint Committee on Cancer Study
Por:
Tomar AS, Finger PT, Gallie B, Kivelä TT, Mallipatna A, Zhang C, Zhao J, Wilson MW, Brennan RC, Burges M, Kim J, Berry JL, Jubran R, Khetan V, Ganesan S, Yarovoy A, Yarovaya V, Kotova E, Volodin D, Yousef YA, Nummi K, Ushakova TL, Yugay OV, Polyakov VG, Ramirez-Ortiz MA, Esparza-Aguiar E, Chantada G, Schaiquevich P, Fandino A, Yam JC, Lau WW, Lam CP, Sharwood P, Moorthy S, Long QB, Essuman VA, Renner LA, Semenova E, Català-Mora J, Correa-Llano G and Carreras-Bertran E
Publicada:
1 ago 2022
Ahead of Print:
1 jul 2022
Categoría:
Ophthalmology
Resumen:
Purpose: To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features.
Design: International, multicenter, registry-based retrospective case series.
Participants: Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma.
Methods: International, multicenter, registry-based data were pooled from patients enrolled between 2001 and 2013. High-risk pathologic features were defined as AJCC categories pT3 and pT4. In addition, AJCC OOTF Size Groups were defined as follows: (1) less than half, (2) more than half but less than two thirds, (3) more than two thirds of globe volume involved, and (4) diffuse infiltrating retinoblastoma.
Main Outcome Measures: Statistical risk of high-risk pathologic features corresponding to AJCC cT3 subcategories and AJCC OOTF Size Groups.
Results: Of 942 retinoblastoma eyes treated by primary enucleation, 282 (30%) showed high-risk pathologic features. Both cT subcategories and AJCC OOTF Size Groups (P < 0.001 for both) were associated with high-risk pathologic features. On logistic regression analysis, cT3c (iris neovascularization with glaucoma), cT3d (intraocular hemorrhage), and cT3e (aseptic orbital cellulitis) were predictive factors for high-risk pathologic features when compared with cT2a with an odds ratio of 2.3 (P = 0.002), 2.5 (P = 0.002), and 3.3 (P = 0.019), respectively. Size Group 3 (more than two-thirds globe volume) and 4 (diffuse infiltrative retinoblastoma) were the best predictive factors with an odds ratio of 3.3 and 4.1 (P < 0.001 for both), respectively, for high-risk pathologic features when compared with Size Groups 1 (i.e., < 50% of globe volume).
Conclusions: The AJCC retinoblastoma staging clinical cT3c-e subcategories (glaucoma, intraocular hemorrhage, and aseptic orbital cellulitis, respectively) as well as the AJCC OOTF Size Groups 3 (tumor more than two thirds of globe volume) and 4 (diffuse infiltrative retinoblastoma) both allowed stratification of clinical risk factors that can be used to predict the presence of high-risk pathologic features and thus facilitate treatment decisions. (C) 2022 by the American Academy of Ophthalmology.
Filiaciones:
Tomar AS:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Finger PT:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Gallie B:
The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada
Kivelä TT:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Mallipatna A:
The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada
Department of Ocular Oncology, Narayana Nethralaya Eye Hospital, Bangalore, India
Zhang C:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Zhao J:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Wilson MW:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Brennan RC:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Burges M:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Kim J:
USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California
The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA
Berry JL:
USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California
The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA
Jubran R:
USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California
The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA
Khetan V:
Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Ganesan S:
Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Yarovoy A:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Yarovaya V:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Kotova E:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Volodin D:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Yousef YA:
Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan
Nummi K:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Ushakova TL:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Medical Academy of Postgraduate Education, Moscow, Russian Federation
Yugay OV:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Polyakov VG:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Medical Academy of Postgraduate Education, Moscow, Russian Federation
Ramirez-Ortiz MA:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Esparza-Aguiar E:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Chantada G:
Hemato-Oncology service, Hospital Sant Joan de Déu, Barcelona, Spain
Schaiquevich P:
Precision Medicine Coordination Hospital JP Garrahan, Buenos Aires, Argentina and CONICET, National Scientific and Technical Research Council, Argentina
Fandino A:
Ophthalmology Service Hospital JP Garrahan, Buenos Aires, Argentina
Yam JC:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong
Lau WW:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong
Lam CP:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong
Sharwood P:
Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Australia
Moorthy S:
KK Women's and Children's Hospital, Singapore
Long QB:
KK Women's and Children's Hospital, Singapore
Essuman VA:
Ophthalmology Unit, Department of Surgery, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana
Renner LA:
Department of Child Health, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana
Semenova E:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Català-Mora J:
Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
:
Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
Carreras-Bertran E:
Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
Green Submitted
|